Cancer Immunology Community Seeks Better End Points

November 29, 2016

Drug developers are still hunting for surrogate end points that can better capture the benefits of checkpoint inhibitors, oncolytic viruses and modified T cell therapies.

Continue reading here.

Clock face, DNA strand and assortment of animals: dolphins, deer, bears, whale, baboon
By Elie Dolgin September 22, 2025
Molecular signatures of aging are changing how conservationists assess population health, resilience and risk.
Yellow rings of DNA amidst white chromosomes
By Elie Dolgin September 11, 2025
Paul Mischel is championing the importance of odd rings of DNA in tumors — and their promise as targets for cancer therapy.